Contingency in innovation and the role of national systems: Taxol and taxotère in the USA and France

Research Policy

Volumn 33, Issue 9, 2004, Pages 1307-1327

  Walsh, Vivien ^a   Le Roux, Muriel ^b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b ECOLE NORMALE SUPÉRIEURE   (France)

Author keywords

France; National innovation system; Pharmaceuticals; Taxol; USA

Indexed keywords

DRUG PRODUCTS; INDUSTRIAL ECONOMICS; INTELLECTUAL PROPERTY; MARKETING; PRODUCT DEVELOPMENT; PROJECT MANAGEMENT; RESEARCH AND DEVELOPMENT MANAGEMENT; TECHNOLOGY TRANSFER;

FRANCE; NATIONAL INNOVATION SYSTEM; TAXOL; USA;

RESEARCH;

EID: 20444373697     PISSN: 00487333     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.respol.2004.07.009     Document Type: Article

References (81)

1. M. Albert Capitalisme contre capitalisme 1991 Le Seuil Paris
2. E. Arnold, and K. Guy Parallel Convergence 1986 Frances Pinter London
3. Aventis, 2003. Accessed on 1 October 2003. http://www.aventispharma-us. com/main/0,1003,EN-US-28455-45933 -,FF.html.
4. C.G. Baker Cancer research program strategy and planning - the use of contracts for program implementation Journal of National Cancer Institute 59 Suppl. 2 1977 651 670
5. M. Bauer The politics of state-directed privatisation: the case of France West European Politics 11 4 1988 49 60
6. M.-C. Bissery, and F. Lavelle The taxoids B.A. Teicher Cancer Therapeutics: Experimental and Clinical Agents 1997 Humana Press Totoowa, NJ 175 193
7. E. Blume Investigators seek to increase taxol supply Journal of National Cancer Institute 81 1989 1122 1123
8. R. Bud Strategy in American Cancer Research after World War. II. A case study Social Studies of Science 8 425-459 1978 433
9. B. Carlsson, S. Jacobsson, M. Holmén, and A. Rickne Innovation systems: analytical and methodological issues Proceedings of the Druid Conference on National Innovation Systems Industrial Dynamics and Innovation Policy, Rebild, 9-12 June 1999
10. M. Cassier Private property, collective property and public property in the age of genomics International Social Science Journal 171 2002 83 98
11. G. Chauvière, D. Guénard, F. Picot, V. Sénilh, and P. Potier Analyse structurale et étude biochimique de produits isolés de l'If Comptes Rendus de l'Académie des Sciences de Paris, Série II 293 1981 501 503
12. S. Chesnoff The use of taxol as a trademark Nature 374 1995 208 (see also editorial: Names for hi-jacking, Nature 373 (1995) 370)
13. CNRS, 2003. Implication du CNRS dans la recherché sur le cancer. Accessed on 18 September 2003. http://www.cnrs.fr/sdv/cnrscancer.html.
14. R. Coghill Preclinical program: plan of action - its philosophy and implementation Cancer Chemotherapy Reports 7 29-41 1960 4
15. Colin, M., Guénard, D., Guéritte-Voegelein, F., Magnatal, L., Potier, P., 1988. Preparation of baccatin III derivatives as antitumour agents. French Patent 884,513 (6 April); See also European Patent EP 336,851 (11 October 1989).
16. Colin, M., Guénard, D., Guéritte-Voegelein, F., Potier, P., 1989a. Taxol derivatives, their preparation and pharmaceutical compositions containing them. US Patent 4,814,470 (filed 14 July 1987; granted 21 March 1989).
17. Colin, M., Guénard, D., Guéritte-Vogelein, F., Potier, P., 1989b. Process for the preparation of taxol and 10-deacetyltaxol. US Patent 4,857,653 (filed 14 July 1987; granted 15 August 1989).
18. Commission d'Orientation sur le Cancer, 2003. Rapport. Accessed on 11 September 2003. http://www.sante.gouv.fr/htm/dossiers/cancer/intro.htm.
19. Cragg, G., 1988. Trip Report, Oregon and Washington, 17-22 April, FRD2.
20. J.-N. Denis, A.E. Greene, D. Guénard, F. Guéritte- Voegelein, L. Mangatal, and P. Potier A highly efficient practical approach to natural taxol Journal American Chemical Society 110 1988 5917 5919
21. de Tricornet, A., 2002. Le portefeuille d'actions de l'Etat est victime de la volatilité des marches. Le Monde, 5 September.
22. C. Edquist Systems of Innovation: Technologies, Institutions and Organizations 1997 Pinter Press Washington, DC
23. R. Eisenberg Public research and private development: patents and technology transfer in government sponsored research Virginia Law Review 8 8 1996 1663 1727
24. K.M. Endicott The chemotherapy program Journal of National Cancer Institute 19 1957 275 293
25. Federal Register, 1989. 54, no. 146, 1 August 1989, pp. 31734-31735.
26. D. Foray The Economics of Knowledge 2004 MIT Press Cambridge, MA
27. C. Freeman Technology Policy and Economic Performance: Lessons from Japan 1987 Pinter Publishers London
28. Freeman, C., 1989. The third Kondratieff wave: age of steel, electrification and imperialism. In: Bohlin, et al. (Eds.), Samhä llsvetenskap Ekonomi och Historia, Daidalos, Göterborg (English translation available from Science Policy Research Unit, Sussex University).
29. C. Freeman The 'National System of Innovation' in historical perspective Cambridge Journal of Economics 19 1995 5 24
30. J-P. Gaudillière Inventer la biomédecine, La France, l'Amérique et la production des savoirs du vivant (1945-1965) 2002 La Découverte Paris pp. 1945-1965
31. Gaudillière, J-P., Löwy, I., in press. Science, markets and public health: contemporary testing for breast cancer predisposition. In: Berridge, V., Loughlin, K. (Eds.), Medicine, the Market and Mass Media: Producing Health in the Twentieth Century. Routledge, London.
32. J. Goodman, and V. Walsh The Story of Taxol: Nature and Politics in the Pursuit of an Anticancer Drug 2001 Cambridge University Press New York
33. K. Green, V. Walsh, and A. Richards Differences in 'styles' of technological innovation: an introduction Technology Analysis and Strategic Management 10 4 1998 403 406 and the collection of papers in the same issue
34. F. Guéritte-Voegelein, V. Sénilh, B. David, D. Guénard, and P. Potier Chemical studies of 10-deacetyl baccatin. III. Hemisynthesis of taxol derivatives Tetrahedron 42 1986 4451 4460
35. C. Hayden A biodiversity sampler for the millennium S. Franklin H. Ragoné Reproducing Reproduction vols. 171-206 1998 University of Pennsylvania Press Philadelphia 186 187
36. Holton, R., 1990. Method for preparation of taxol using an oxazinone. European Patent 400,971; US Patent 5,015,744 (1991).
37. Holton, R., 1991. Method for preparation of taxol using a β-lactam. European Patent 428,376; US Patent 5,175,315 (1992) (modified version, easier to scale up).
38. J. Kloppenburg First the Seed: The Political Economy of Plant Biotechnology 1492-2000 1988 Cambridge University Press Cambridge, UK
39. P. Larédo, and P. Mustar Research and Innovation Policies in the New Global Economy 2001 Edward Elgar Cheltenham
40. Le Monde, 1999. La France Mondialisée, 16 March.
41. M. Le Roux Genèse des textes de Pierre Potier, chimiste des substances naturelles Genesis 20 2003 91 126
42. Le Roux, M., in press. Ce que l'histoire des brevets révèle des relations ambiguës entre science et industrie, l'exemple de l'ICSN, in Mousnier-Kuhn, P. E., Les brevets dans l'histoire, L'Harmattan, Paris.
43. B.-Å. Lundvall National Systems of Innovation: Towards a Theory of Innovation and Interactive Learning 1992 Pinter Publishers London
44. B.-Å. Lundvall Why study national systems and national styles of innovation? Technology Analysis and Strategic Management 10 4 1998 407 421
45. R. Mazzoleni, and R. Nelson The benefits and costs of strong patent protection: a contribution to the current debate Research Policy 27 1998 273 284
46. R. Merges, and R. Nelson On limiting or encouraging rivalry in technical progress: the effect of patent scope decisions Journal of Economic Behaviour and Organisation 25 1994 1 24
47. F. Morin Le Modèle Français de Détention et de Gestion du Capital 1998 Bercy Paris
48. D.C. Mowery, R.R. Nelson, B.N. Sampat, and A.A. Ziedonis The growth of patenting and licensing by US Universities: an assessment of the effects of the Bayh-Dole act of 1980 Research Policy 30 1980 99 119
49. P. Mustar La politique de l'innovation en France: le colbertisme entamé F. Sachwald Les Défis de la Mondialisation: Innovation et Concurrence 1994 Masson Paris
50. P. Mustar, and P. Larédo Innovation and research policy in France (1980-2000) or the disappearance of the Colbertist state Research Policy 31 2002 55 72
51. NCI, 1958. Patent policy applicable to cancer chemotherapy industrial research contracts, press release, 5 August, approved 31 July. National Cancer Institute Archives AR 2524.
52. NCI, 1987. Annual Report to the Food and Drug Administration: Taxol. Division of Cancer Treatment, National Cancer Institute, March.
53. R. Nelson National Innovation Systems 1993 Oxford University Press New York
54. R.L. Noble The discovery of the vinca alkaloids - chemotherapeutic agents against cancer Biochemistry and Cell Biology 68 1990 1344 1351
55. OECD, 1981. Science and Technology Indicators. Organisation for Economic Co-operation and Development, Paris.
56. OECD, 2003. Main Science and Technology Indicators. Organisation for Economic Co-operation and Development, Paris.
57. Patel, P., Pavitt, K., 1993. National systems of innovation: why they are important, and how they might be defined, compared and assessed. Document de travail no 93/05 du seminaire d'analyse économique, LATAPSES Unité de Recherche du CNRS, Université de Nice, Sophia Antipolis, France.
58. R. Perdue, and J. Hartwell The search for plant sources of anticancer drugs Morris Arboretum Bulletin 20 1969 35 53
59. J.-F. Picard Poussée scientifique ou demande de médecins? La recherche médicale en France de l'Institut National d'Hygiène à l'INSERM Sciences Sociales et Santé X 4 1992 47 105
60. P. Pinell Naissance d'un Fléau: La lutte contre le cancer en France 1994 Métallié Paris
61. P. Potier Contribution of an organic chemist to the resolution of some biological problems - consequences Pure and Applied Chemistry 58 1986 737 744
62. P. Potier Search and discovery of new antitumour compounds. Rhône Poulenc lecture Chemical Society Reviews 21 1992 113 119
63. P. Potier, D. Guénard, and F. Zavala Current results in the field of vinblastine antitumor alkaloids. Biochemical studies Comptes Rendus de la Société de Biologie 173 1979 2175 2179
64. C.P. Rhoads Nitrogen mustards in the treatment of neoplastic disease. Official statement Journal of the American Medical Association 131 1946 656 658
65. RTI, 1967. Research Triangle Institute Progress Report no. 21, 26 June, p. 4.
66. Santé, 2003. Commission d'Orientation sur le Cancer, Rapport 2003. Accessed on 11 September 2003. http://www.sante.gouv.fr/htm/dossiers/cancer/ intro.htm.
67. S.A. Schepartz History of the National Cancer Institute and the plant screening program Cancer Treatment Reports 60 1976 975 977
68. V. Sénilh, F. Guéritte, D. Guénard, M. Colin, and P. Potier Comptes Rendus de l'Academie des Sciences de Paris, Série II 299 1984 1039 1043
69. M. Shear The role of the chemotherapy research laboratory in clinical cancer research Journal of the National Cancer Institute 12 1951 569 581
70. M.L. Shelanski, F. Gaskin, and C.R. Cantor Microtubule assembly in the absence of added nucleotides Proceedings of the National Academy of Sciences 70 1973 765 768
71. Stephenson, F., 2002. Ideas that move: a tale of taxol. Florida State University website accessed on 11 September 2003. http://www.research.fsu.edu/ researchr/fall2002/taxol.html.
72. Strycker, L., 1987. Cancer cure may be in common yew. The Register-Guard, 7 April, 1B.
73. M. Suffness, and J. Douros Current status of the NCI plant and animal product program Journal of Natural Products 45 1982 1 14 (see also note 167, p. 44, Goodman and Walsh, 2001)
74. C. Swindell Taxane diterpene synthesis strategies - a review Organic Preparations and Procedures International 23 1991 465 543
75. A. Thayer Bristol-Myers to settle suits Chemical and Engineering News 18 2 2003 6
76. USGAO, 2003. Technology Transfer: NIH-Private Sector Partnership in the Development of Taxol, US General Accounting Office, Report to the Hon. Ron Wyden, US Senate, GAO-03-829.
77. V. Walsh Paradigms in the evolution of life sciences research, and the changing structure of the innovative organisation K. Grandin N. Wormbs S. Widmalm The Science-Industry Nexus: History, Policy, Implications 2004 Science History Publications Canton, MA
78. M.C. Wani, H.L. Taylor, M.E. Wall, P. Coggon, and A.T. Mc Phail Plant antitumour agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumour agent from Taxus brevifolia Journal of the American Chemical Society 93 1971 2325 2327
79. Wood Jr., H.B., 1977. Selection of agents for the tumour screen of potential new anti-neoplastic drugs. In: Saunders, J., Carter, S. (Eds.), Methods of Development of New Anticancer Drugs, National Cancer Institute Monograph 45, vols. 15-35, National Cancer Institute, Bethesda, MD, p. 15.
80. C.G. Zubrod Origins and development of chemotherapy research at the National Cancer Institute Cancer Treatment Reports 68 9-19 1984 11
81. C.G. Zubrod, S. Schepartz, J. Leiter, K.M. Endicott, L.M. Carrese, and C.G. Baker The chemotherapy program of the National Cancer Institute: history, analysis and plans Cancer Chemotherapy Reports 50 1966 349 350